Pfizer's dermatology drug trial results are positive, but stock price still declines

LootboxPhobia · 2026-03-09T12:27:27+00:00

Pfizer's stock price fell by 1.15% to $26.74, despite positive results in mid-stage clinical trials of its antibody therapy tilrekimig for treating atopic dermatitis, showing significant improvement in patient symptoms. The company plans to initiate late-stage trials and explore the application of this drug in other diseases.

LootboxPhobia

2026-03-09 12:27:27

Abstract generation in progress

Investing.com – Pfizer Inc. (NYSE:PFE) stock price fell 1.15% to $26.74 in pre-market trading on Monday, despite the company announcing positive results from mid-stage clinical trials of its experimental antibody therapy for atopic dermatitis.

The pharmaceutical company stated that its antibody drug tilrekimig successfully alleviated symptoms of this chronic itchy skin condition in the study. The company said that, compared to placebo, after 16 weeks, the therapy helped more patients achieve 75% symptom improvement.

Pfizer indicated that the antibody drug was well tolerated in the trial.

The company plans to initiate late-stage trials of tilrekimig later this year. Pfizer is also testing the drug as a potential treatment for asthma and chronic obstructive pulmonary disease.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.